Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
PROKIDNEY CORP.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. – August 10, 2023 – ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease , today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. “In the second quarter, and throughout the first half of 2023, we steadily advanced our REACT development programs, including our initial Phase 3 study, proact 1, that is assessing the potential for REACT to delay or halt the progression of moderate to severe diabetic CKD,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Looking ahead, we expect to reach s..." |
|
| 07/18/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC WINSTON-SALEM, N.C., July 18, 2023 — ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease , today announced it has closed on its purchase of a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C. ProKidney paid approximately $25.5 million in cash for the facility and property. The Company plans to make investments in the facility through 2028 to prepare for potential commercial-scale manufacturing of REACT®, its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic CKD. In connection with the purchase, the city of ..." |
|
| 06/30/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC WINSTON-SALEM, N.C., June 13, 2023 — ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease , today announced its agreement to purchase a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C., to support the Company's future commercial manufacturing needs for REACT ® , its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic CKD. Under the purchase agreement, ProKidney will pay approximately $25.5 million in cash for the facility and property. The transaction is expected to close by the end of June 2023, subject to customary cl..." |
|
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C. – May 11, 2023 – ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease , today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments. “During the first quarter of 2023, we continued to advance the Phase 3 clinical development of REACT® to assess its potential to delay and possibly eliminate the need for dialysis, and in parallel we sharpened our plans for manufacturing and organizational development as we progress toward potential commercialization,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Patient enrollment in proact ..." |
|
| 03/28/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Investor presentation |
| 02/06/2023 |
8-K
| Quarterly results |
| 01/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/10/2023 |
8-K
| Investor presentation |
| 12/06/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/08/2022 |
8-K
| Investor presentation|
Docs:
|
"82.2 40, 112, 153 93, 213, 191 228,60, 102 165,165,165 69, 195, 255 68, 84, 106" |
|
| 07/15/2022 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...|
Docs:
|
"Second Amended & Restated Memorandum and Articles of Association of ProKidney Corp",
"Tax Receivable Agreement, by and among ProKidney Corp. (formerly known as Social Capital Suvretta Holdings Corp. III), the TRA Party Representative (as defined therein) and the TRA Parties (as defined therein)",
"Exchange Agreement, by and among ProKidney Corp. (formerly known as Social Capital Suvretta Holdings Corp. III), ProKidney LP, acting through its general partner ProKidney Corp. GP Limited, and certain holders named therein",
"Lock-up Agreement, by and among ProKidney Corp. (formerly known as Social Capital Suvretta Holdings Corp. III), SCS Sponsor III LLC, the Sponsor Key Holders (as defined therein) and the ProKidney Holders (as defined therein)",
"Amended and Restated Registration Rights Agreement, by and among ProKidney Corp. (formerly known as Social Capital Suvretta Holdings Corp. III), SCS Sponsor III LLC, the ProKidney Holders (as defined therein), Marc Semigran, Uma Sinha, Sukumar Nagendran, David Spiegel and the Investor Stockholders (as defined therein)",
"Second Amended and Restated Limited Partnership Agreement for a Limited Partnership Called ProKidney LP, by and among Tolerantia, LLC, Control Empresarial de Capitales, S.A. de C.V., ProKidney Management Equity LLC, ProKidney Corp. (formerly known as Social Capital Suvretta Holdings Corp. III), ProKidney Corp. GP Limited and ProKidney GP Limited",
"Tax Receivable Agreement, by and among ProKidney Corp. (formerly known as Social Capital Suvretta Holdings Corp. III), the TRA Party Representative (as defined therein) and the TRA Parties (as defined therein)",
"ProKidney Corp. Employee Stock Purchase Plan",
"Tax Receivable Agreement, by and among ProKidney Corp. (formerly known as Social Capital Suvretta Holdings Corp. III), the TRA Party Representative (as defined therein) and the TRA Parties (as defined therein)",
"Letter from Marcum LLP to the SEC" |
|
| 07/12/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 07/06/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K/A
| Quarterly results |
| 04/28/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 01/21/2022 |
8-K/A
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 01/18/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat... |
| 11/16/2021 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 09/24/2021 |
8-K
| Quarterly results |
| 07/09/2021 |
8-K
| Quarterly results |
| 07/02/2021 |
8-K
| Appointed a new director|
Docs:
|
"Underwriting Agreement, between the Company and Morgan Stanley & Co. LLC",
"Amended and Restated Memorandum and Articles of Association of the Company",
"Letter Agreement, among the Company, the Sponsor and the Company's officers and directors",
"Investment Management Trust Agreement, between the Company and Continental Stock Transfer & Trust Company, as trustee",
"Registration Rights Agreement, among the Company and certain other security holders named therein",
"Administrative Services Agreement, between the Company and Social + Capital Partnership, LLC",
"Private Placement Shares Purchase Agreement, between the Company and the Sponsor",
"Form of Indemnity Agreement, between the Company and each of its officers and directors",
"Social Capital Suvretta Holdings Corp. III Announces Pricing of Upsized $220,000,000 Initial Public Offering PALO ALTO, Calif., Jun. 30, 2021 /Business Wire/ - Social Capital Suvretta Holdings Corp. III announced today that it has priced its upsized initial public offering of 22,000,000 Class A ordinary shares at $10.00 per share. The Class A ordinary shares will be listed on the Nasdaq Capital Market and trade under the ticker symbol “DNAC” beginning June 30, 2021. The Company is led by Chamath Palihapitiya and Kishen Mehta and is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on businesses operating ..." |
|
|
|